Key Takeaways
- In 2020, the Food and Drug Administration (FDA) said it had approved no stem cell product to treat autism.
- A 2020 trial of 180 children found that one cord blood infusion did not improve social skills more than a placebo.
- Smaller studies with no comparison group reported gains, but they cannot show that the cells caused them.
- The International Society for Stem Cell Research lists parent stories, hidden costs and unclear cell sources as warning signs.
- The Centers for Disease Control and Prevention says behavioral approaches have the most evidence for treating autism.
Estimated read: 9 min
Clinics widely market stem cell programs for autism. Yet a 2020 trial of 180 children found no overall benefit from cord blood. This guide gives parents the red flags that signal weak claims and a plain view of the evidence.
What are stem cell programs for autism?
Stem cell programs for autism are paid packages that give children cells from umbilical cord blood or umbilical cord tissue. A 2022 review in Frontiers in Pediatrics noted that programs differ in injection routes and doses. Providers hope the cells will ease autism spectrum disorder symptoms.
Some researchers link autism with immune activity in the brain. A 2026 journal review cautions that this link does not show the immune system causes autism. This guide to stem cell programs for autism: red flags and evidence therefore tests cell treatment against trial results.
Which types of stem cells do autism programs use?
A 2026 review found that autism studies used umbilical cord blood, umbilical cord tissue and bone marrow cells.
These types of stem cells differ in what they contain. Cord blood holds a mix of blood cells, including immune cells. Umbilical cord tissue contains mesenchymal stem cells, which release anti inflammatory signals in lab studies.
| Cell type | Where it comes from | What studies report |
|---|---|---|
| Cord blood cells | Blood left in the umbilical cord after birth | A 2020 trial of 180 children found no overall benefit |
| Mesenchymal stem cells | Umbilical cord tissue, bone marrow or other tissue | A 2026 review says benefit remains unresolved |
| Bone marrow cells | Marrow from the child or a donor | Small studies with mixed designs |
Researchers hope these cells may calm inflammation that affects brain cells. However, the 2026 review states that this reasoning alone cannot predict benefit. It also reports that no clinical study has shown one cord source to work better than another.
Cyrona Cell’s earlier article explains how stem cells may work for autism in more detail. According to Cyrona Cell’s autism treatment page, the cells it uses are umbilical cord derived.
Is stem cell therapy approved for autism?
In 2020, the United States Food and Drug Administration (FDA) said it has approved no stem cell product to treat autism. Its 2020 alert on stem cells and exosomes lists blood-forming cells from cord blood as the only approved products. Doctors use those products only for disorders that affect blood production.
The International Society for Stem Cell Research (ISSCR) published a patient guide in 2024. It notes that an experimental label does not make a program a research study. Real clinical trials have ethics review and written consent forms.
Cyrona Cell’s overview of what remains experimental for autism explains that stem cell therapy is not standard care.
What do clinical trials show about autism?
Clinical trials of cells for autism showed short-term safety. Evidence of benefit remains unresolved.
Early studies had no comparison group. A later trial added a placebo group. Later reviews combined the results of these studies.
| Study | Who took part | What happened | What it means |
|---|---|---|---|
| 2017 Duke study | 25 children, no comparison group | Better scores 6 and 12 months after own cord blood | Shows safety, but not that the cells caused the gains |
| 2020 Duke trial | 180 children, with a placebo group | No overall gain in social skills or symptoms at 6 months | No overall benefit in this trial |
| 2022 review | Five pooled studies | Lower scores on one scale, similar doctor ratings | Limited by small studies and short follow-up |
| 2026 conference abstract | 22 pooled studies | Large average gain, very uneven results | Includes studies where families knew about treatment |
What did the first cord blood study find?
A 2017 Duke University study of 25 children reported that children tolerated infusions of their own cord blood well. Parent reports, clinician ratings, and eye-tracking tests all showed better scores at 6 and 12 months. However, the study had no comparison group, so it could not show that the cord blood caused those gains.
The authors designed it to test safety and select outcome measures for later trials.
What did the 2020 trial with a placebo group find?
A 2020 trial of cord blood in 180 children found no overall gain in social skills or autism symptoms. Fifty-six children received their own cord blood, 63 received donor cord blood, and 61 received a placebo, a dummy infusion. Neither families nor researchers knew who received which, and the team checked results after 6 months.
The infusions were safe and well tolerated. Among children without intellectual disability, those given donor cord blood improved more on one doctor-rated scale. However, chance could explain that gap, and the authors called for more research.
What do reviews that pool many studies say?
Reviews that pool small studies report better scores after stem cells, yet the pooled studies have important limits.
In Frontiers in Pediatrics, a 2022 review pooling five stem cell studies compared children with and without cells. Scores on one autism rating scale were lower after stem cells. However, the 2022 review found a doctor-rated scale improved in 62% of the stem cell group and 60% of the comparison group.
The authors cited small studies, varied doses and routes, and short follow-up. They called for larger trials.
A 2026 conference abstract in European Psychiatry pooled 22 studies and reported a large average gain. However, it included studies where families knew their child received the cells, and results varied widely. Only three studies compared stem cells with a placebo.
A 2026 review of cord-derived cells in autism found short-term safety to be the most consistent result across five published trials. Benefit remained unresolved because the studies were small and varied in design. A randomized trial of a cord tissue cell product, so far posted only in a registry, did not reach its main goal.
What are the risks and side effects of stem cell therapy?
The safety of stem cell therapy for autism looked acceptable in the 2017 and 2020 trials, but follow-up was short. Research shows that follow-up lasted 12 months in 2017 and 6 months in 2020. Long-term effects remain unknown, and the ISSCR guide urges long-term safety checks because transplanted cells may stay for years.
A 2026 review reports new antibodies against donor cells in five of 12 children who received donor cord tissue cells. None had symptoms. That finding shows researchers are still mapping the safety profile of donor cells.
The ISSCR guide warns that unproven treatments can cause physical, psychological and financial harm. It also notes that many clinics selling them lack rigorous systems for reporting side effects.
What are the red flags in stem cell programs for autism?
The 2024 ISSCR guide to stem cell treatments names several warning signs of an unproven treatment.
- Claims based on parents’ stories rather than controlled studies, because a child may improve for unrelated reasons.
- A cell source or method with no clear written record.
- Claims that the treatment carries no risk, even though every treatment carries some risk.
- Fees to join a clinical trial, which trials do not normally charge.
- Hidden costs, such as emergency care after a complication.
Any one of these signs warrants a pause and a closer look. Because stem cell programs for autism vary widely, the guide also encourages a second opinion from an independent doctor.
How can parents check the evidence behind a program?
Parents can check the evidence by asking for published studies of the same cell product, dose and group of children.
- A named cell product that lists its source, dose, and batch testing.
- Written treatment protocols that serve as the procedure’s operating manual.
- A signed consent form that lists the risks and states clearly that the treatment is unproven.
- An independent doctor’s view after reviewing the child’s full medical history.
A listing among clinical trials in a public registry is not proof of approval. The ISSCR guide notes that a database entry does not prove a treatment works or has regulatory oversight.
The guide says these products contain living cells, so makers must test each batch for consistency and safety. A Cyrona Cell summary of one 2026 study explains why cell quality testing matters.
Where do standard autism therapies fit in?
The Centers for Disease Control and Prevention (CDC) groups autism treatments into behavioral, developmental, educational, social and psychological approaches. Its autism treatment overview says behavioral approaches have the most evidence for treating autism symptoms. Families should keep these evidence based therapies in place.
Any cell treatments a family considers should sit alongside this care, not replace it. The CDC also advises talking to a doctor before starting any complementary or alternative treatment. Nobody should stop a medicine or therapy without their own doctor’s advice.
After an enquiry, the process runs from shared reports to a personal plan. Families can read how the Cyrona Cell process works.
Frequently Asked Questions About Autism Programs
Is stem cell therapy FDA-approved for autism?
The FDA has approved no stem cell product to treat autism, according to its 2020 consumer alert. Its 2020 alert says the only approved stem cell products are blood-forming cells for blood disorders.
What types of cells do researchers use?
Researchers gave children cord blood cells, bone marrow cells or mesenchymal stem cells from umbilical cord tissue. A 2026 review reports that these studies were small and varied in design. No clinical study has shown that one cell source works better than another.
What are the potential risks?
The main risks are unknown long-term effects, since trials followed children for only 6 to 12 months. Both the 2017 and 2020 trials described the infusions as safe and well tolerated. The ISSCR guide also warns that unproven treatments can cause physical, psychological and financial harm.
How can parents find a genuine clinical trial?
Parents can use the ClinicalTrials.gov search for studies and ask their child’s doctor which studies suit their child. The 2024 ISSCR guide says trials do not normally charge participants a fee. Not every trial appears in a registry, so a doctor’s advice still matters.
Talk to Cyrona Cell About Stem Cell Programs for Autism
Parents weighing stem cell programs for autism can ask the Cyrona Cell team their questions on WhatsApp. Sharing your child’s reports helps the team explain what the research shows and doesn’t show, and whether treatment may be suitable.
Cyrona Cell has its office in Cyberjaya, Malaysia, and arranges treatment at partner facilities in Kuala Lumpur. Parents may also email the Cyrona Cell team at info@cyronacell.com.
This article is for information only and does not replace advice from your child’s own doctor.
